Form 4: Vaxcyte COO Jim Wassil Executes Stock Sale

Vaxcyte Chief Operating Officer Jim Wassil sold 2,250 shares of common stock pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., sold 2,250 shares of common stock.
• The transaction occurred on May 1, 2026, at a weighted-average price of $56.831 per share.
• Following the sale, the reporting person retains beneficial ownership of 160,744 shares of Vaxcyte common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on December 9, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially signaling a lack of confidence in future performance, though this specific sale was pre-planned.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are common in the biotechnology sector and are generally viewed as routine liquidity events rather than indicators of company health.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and represents a small percentage of the executive's total ownership.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Vaxcyte, PCVX, Insider Trading, Form 4, Biotech, Executive Compensation